Skip to main content

Shepler Robert G's Form 4 filing

Akoya Biosciences, Inc. (AKYA) · filed Nov 18, 2021

Accession no.
0001104659-21-141484
Filed
Nov 18, 2021
Trade date
Nov 18, 2021
Filing delay
Same day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions. Open-market purchases total $441.1K. It was filed on the trade date.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Shepler Robert GCIK 0001113663Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 18, 2021Common StockPPurchaseAcquired+15,000$12.17F1+$182,55015,000Direct
Nov 18, 2021Common StockPPurchaseAcquired+20,000$12.93F2+$258,60035,000Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Column 4 reflects a weighted average price. Shares were sold in multiple transactions at prices ranging from $11.85-$12.75. Reporting person undertakes to provide issuer, securityholder of issuer or SEC staff, upon request, information regarding number of shares sold at each separate price within the range set forth herein.

Referenced by the price of 1 transaction in Table I.

F2

Column 4 reflects a weighted average price. Shares were sold in multiple transactions at prices ranging from $12.85-$13.00. Reporting person undertakes to provide issuer, securityholder of issuer or SEC staff, upon request, information regarding number of shares sold at each separate price within the range set forth herein.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)